Cargando…

Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc

BACKGROUND: Entry of human immunodeficiency virus type 1 (HIV-1) into cells involves the interaction of the viral gp120 envelope glycoproteins (Env) with cellular CD4 and a secondary coreceptor, which is typically one of the chemokine receptors CCR5 or CXCR4. CCR5-using (R5) HIV-1 strains that displ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borm, Katharina, Jakobsen, Martin R., Cashin, Kieran, Flynn, Jacqueline K., Ellenberg, Paula, Ostergaard, Lars, Lee, Benhur, Churchill, Melissa J., Roche, Michael, Gorry, Paul R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093974/ https://www.ncbi.nlm.nih.gov/pubmed/27809912 http://dx.doi.org/10.1186/s12977-016-0309-2

Ejemplares similares

Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection
por: Jakobsen, Martin R., et al.
Publicado: (2013)

Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection
por: Cashin, Kieran, et al.
Publicado: (2013)

Differences in coreceptor specificity contribute to alternative tropism of HIV-1 subtype C for CD4(+) T-cell subsets, including stem cell memory T-cells
por: Cashin, Kieran, et al.
Publicado: (2014)

Quantifying Susceptibility of CD4(+) Stem Memory T-Cells to Infection by Laboratory Adapted and Clinical HIV-1 Strains
por: Flynn, Jacqueline K., et al.
Publicado: (2014)

Covariance of Charged Amino Acids at Positions 322 and 440 of HIV-1 Env Contributes to Coreceptor Specificity of Subtype B Viruses, and Can Be Used to Improve the Performance of V3 Sequence-Based Coreceptor Usage Prediction Algorithms
por: Cashin, Kieran, et al.
Publicado: (2014)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
por: Roche, Michael, et al.
Publicado: (2011)

CoRSeq(V3-C): a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm
por: Cashin, Kieran, et al.
Publicado: (2013)

Understanding the mechanisms driving the spread of subtype C HIV-1
por: Gartner, Matthew J., et al.
Publicado: (2020)

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
por: Roche, Michael, et al.
Publicado: (2013)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies
por: Chikere, Kelechi, et al.
Publicado: (2014)

Reliable Genotypic Tropism Tests for the Major HIV-1 Subtypes
por: Cashin, Kieran, et al.
Publicado: (2015)

Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
por: Poveda, Eva, et al.
Publicado: (2010)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
por: Pujari, Sanjay, et al.
Publicado: (2018)

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
por: Cooper, David A., et al.
Publicado: (2014)

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey
por: De Luca, Andrea, et al.
Publicado: (2019)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Longitudinal analysis of subtype C envelope tropism for memory CD4(+) T cell subsets over the first 3 years of untreated HIV-1 infection
por: Gartner, Matthew J., et al.
Publicado: (2020)

Genotypic Prediction of Co-receptor Tropism of HIV-1 Subtypes A and C
por: Riemenschneider, Mona, et al.
Publicado: (2016)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
por: López-Huertas, María Rosa, et al.
Publicado: (2020)

Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients
por: Valdez, H, et al.
Publicado: (2010)

Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa
por: Siddik, Abu Bakar, et al.
Publicado: (2018)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Phage display identifies two Caprine Arthritis Encephalitis Virus env epitopes
por: Gazarian, Karlen, et al.
Publicado: (2011)

Glycosylation of HIV Env Impacts IgG Subtype Responses to Vaccination
por: Heß, Rebecca, et al.
Publicado: (2019)

Envés
por: Amara, Luigi, 1971-
Publicado: (2003)

Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge
por: Borggren, Marie, et al.
Publicado: (2011)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Yeast surface display of HIV Env protein variants for the discovery of novel vaccine immunogens
por: Grimm, S, et al.
Publicado: (2012)

Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis
por: Zheng, Qi, et al.
Publicado: (2012)

The utility of maraviroc, an antiretroviral agent used to treat HIV, as treatment for opioid abuse? Data from MRI and behavioural testing in rats
por: Iriah, Sade C., et al.
Publicado: (2021)

Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment
por: Shikuma, Cecilia M., et al.
Publicado: (2023)

Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses
por: Prévost, Jérémie, et al.
Publicado: (2018)

Design of lipid nanoparticle delivery agents for multivalent display of recombinant Env trimers in HIV vaccination
por: Pejawar-Gaddy, S, et al.
Publicado: (2012)

Design of Lipid Nanocapsule Delivery Vehicles for Multivalent Display of Recombinant Env Trimers in HIV Vaccination
por: Pejawar-Gaddy, Sharmila, et al.
Publicado: (2014)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction
por: Ostrowski, Mario, et al.
Publicado: (2015)

Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant
por: Zhang, Hong, et al.
Publicado: (2005)

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments
por: Hraber, Peter, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kju1le44pd4sg8obl467o90pmb